Related Experiment Video

Updated: May 30, 2026

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
04:36

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

Response of concomitant chronic myelogenous leukemia and chronic lymphocytic leukemia to imatinib mesylate

Ju-Yoon Yoon, Rajat Kumar, Raquel Aloyz

    Leukemia Research
    |August 2, 2011
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
    07:38

    Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

    Published on: June 6, 2025

    Related Experiment Videos

    Last Updated: May 30, 2026

    Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
    04:36

    Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

    Published on: October 17, 2025

    Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
    07:38

    Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

    Published on: June 6, 2025

    Related Concept Videos

    Combination Therapies and Personalized Medicine02:50

    Combination Therapies and Personalized Medicine

    Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
    The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against specific...

    Articles linked to this work by shared authors, journal, and citation graph.

    Response to "Comment on 'Rethinking the evidence for a liquid-liquid transition in water: What decompression experiments reveal'" [J. Chem. Phys. 164, 024506 (2026)].

    The Journal of chemical physics·2026

    Chirality Unlocks Sub-Terahertz Molecular Dynamics In Peptide Nanotubes.

    Small (Weinheim an der Bergstrasse, Germany)·2026

    Contemporary Strategies for Regenerating Dehiscence and Fenestration Defects Around Dental Implants: A Critical Review.

    Nigerian medical journal : journal of the Nigeria Medical Association·2026

    Impact of Graft-Versus-Host Disease Prophylaxis on Long-Term Outcomes in Patients Surviving Beyond Two Years After Allogeneic Transplantation.

    JCO oncology practice·2026

    The CCCH-type zinc-finger Pf MD3 promotes translation for malaria parasite transmission.

    bioRxiv : the preprint server for biology·2026

    ATAD3 megadalton complex in Plasmodium falciparum is essential for mitochondrial and cellular viability.

    PLoS pathogens·2026

    Outpatient step-up dosing of teclistamab and talquetamab in relapsed or refractory.

    Leukemia research·2026

    Advances in diagnosis and treatment of angioimmunoblastic T-cell lymphoma.

    Leukemia research·2026

    Immune-mediated thrombosis in myeloproliferative neoplasms: Pathogenic pathways and clinical relevance.

    Leukemia research·2026

    HTLV-1 and ATL: Decoding Molecular Pathogenesis for Next-Generation Therapies.

    Leukemia research·2026

    Comparison allogeneic hematopoietic stem cell transplantation and chemotherapy for consolidation in acute lymphoblastic leukemia in a Colombian Cohort. A propensity score matching analysis.

    Leukemia research·2026

    Comorbidity burden is a major independent prognostic factor in Waldenström Macroglobulinemia: A national cancer database retrospective study.

    Leukemia research·2026

    Exploring the Expanding Role of Nuclear Receptor LRH-1/NR5A2 in Cell Biology and Immunity.

    International journal of cell biology·2026

    Cuproptosis-related molecular alterations in a neonatal rat model of hypoxic-ischemic brain damage.

    Frontiers in neurology·2026

    Off-Target MAP2K7 Inhibition Drives the Antileukemic Activity of the PD-1/PD-L1 inhibitor ACS-69 in Pediatric T-ALL.

    Research square·2026

    A CRISPR-Cas9 platform for primary human hepatocytes enables arrayed screening and in vivo validation of HBV host factors.

    bioRxiv : the preprint server for biology·2026

    Myeloid differentiation-associated autophagy drives venetoclax resistance in AML.

    Research square·2026

    Structure of full-length APOBEC3B bound to EBV BORF2 reveals coordinated neutralization of a cancer-associated mutator.

    Research square·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us